IL-17 antibody formulations and methods of treatment using same
AssigneeEli Lilly and Company
InventorsVincent John Corvari, Barbara Ann Williams, Patrick Daniel Donovan, Aaron Paul Markham
Life of this patent
Estimating the term…
Abstract
The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
Claims6
A pharmaceutical formulation comprising an anti-IL-17 antibody at a concentration in the range of about 80 mg/ml to about 150 mg/ml, citrate buffer at a concentration of about 20 mM, sodium chloride at a concentration of about 200 mM, polysorbate-80 at a concentration in the range of about 0.02% (w/v) to about 0.03% (w/v), and pH at about 5.7, wherein the anti-IL-17 antibody comprises a light chain variable region given by the amino acid sequence of SEQ ID NO:2, and a heavy chain variable region given by the amino acid sequence of SEQ ID NO:3.
Dependencies are inferred from the claim text.